The board also approved an interim dividend of 150 per cent, i.e. INR 1.5 per equity share of INR 1/- for the year FY23-24.
Aurobindo Pharma Q3 Results: Aurobindo Pharma announced its December quarter results on Saturday, reporting a 14.7 per cent jump in revenue from operations Year-on-Year (YoY) to Rs 7,352 crore with growth seen across multiple businesses.
Net profit after minority interest saw growth of 90.6 per cent to Rs 936 Crore YoY and 23.7 per cent Quarter-on-Quarter (QoQ).
EBITDA before Forex and other income stood at Rs 1,601 crore, while EBITDA margin was 21.8 per cent.
US formulations (excluding Puerto Rico) revenue increased by 28.9 per cent YoY to Rs 3,756 crore (USD 451 million).
Read More: Blinkit will outpace Zomato’s food delivery business: Analysts
Europe formulation revenue increased by 1.6 per cent YoY to Rs 1,728 crore (EUR 193 million).
The company’s API revenue grew by 7.1 per cent YoY to Rs 1,022 crore (USD 123 million).
Growth markets revenue increased by 25.6 per cent YoY to Rs 627 crore (USD 75 million).
Read More: Sweet deal! Mukesh Ambani’s Reliance Consumer buys Paan Pasand maker for Rs 27 crore
The company’s research & development (R&D) spend stood at Rs 398 crore, 5.4 per cent of revenues (vs. Q2 FY24: 4.2 per cent).
It also received final approval for 16 ANDAs including 7 specialty and injectable products from the USFDA.
Interim Dividend
The board also approved an interim dividend of 150 per cent, i.e. INR 1.5 per equity share of INR 1/- for the year FY23-24.
